WHIM Syndrome
3
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Mavorixafor
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
33%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (3)
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
Research Network
Common Treatments
- Mavorixafor2
- No Intervention1
Active Sponsors
- X4 Pharmaceuticals3
- X4 Pharmaceuticals Inc.1
Top Investigators
X4 Pharmaceuticals, Inc.